L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.

[1]  M. Relling,et al.  Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Schrappe,et al.  Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL‐BFM treatment protocols , 1999, British journal of haematology.

[3]  C. Pui,et al.  Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group , 1999, Leukemia.

[4]  M. Valsecchi,et al.  Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. , 1998, Haematologica.

[5]  J. Boos,et al.  Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia , 1997, British journal of haematology.

[6]  H. Kühnel,et al.  L-asparagine-depletion: another opinion. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Zucchetti,et al.  L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  H. Jürgens,et al.  Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. , 1996, European journal of cancer.

[9]  H. Jürgens,et al.  Loss of activity of Erwinia asparaginase on repeat applications. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Coppola,et al.  Comparative pharmacokinetic studies of three asparaginase preparations. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Richards,et al.  Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. , 1990, Medical and pediatric oncology.

[12]  S. Sallan,et al.  In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. , 1989, Cancer research.

[13]  M. Brueck,et al.  Chemical and immunological characteristics of four different L‐asparaginase preparations , 1989, European Journal of Haematology.

[14]  N. Cheung,et al.  Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. , 1986, The American journal of pediatric hematology/oncology.

[15]  R. Gelber,et al.  Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. , 1983, Cancer research.

[16]  J. Cooper,et al.  Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography. , 1982, Clinical chemistry.

[17]  R. Riccardi,et al.  L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. , 1981, Cancer research.

[18]  J. Holland,et al.  Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators. , 1981, Cancer treatment reports.